However, in stage III and IV cancer patients, the antibody was detected in 56% cases that include 51% breast cancer, 62% HCC, 48% colorectal cancer, 54% lung cancer and 64% gastric cancer patients (p < 0.01) indicating a potential use of anti-AEG-1 antibody as a marker of cancer progression [133]. This evidence concerns the gene MTDH and gastric cancer.